Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
Previously Treated Metastatic Non-Small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Conditions: Keywords
Non-small cell lung cancer
Study Type
Study Phase
Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Oxaliplatin
Type: Drug
Overall Status
Not yet recruiting
The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.
Detailed Description
This is a non-randomized trial for patients with previously treated Non-small cell lung cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered Intravenously on day 1 and day 8 every 21 days.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemo.

- Measurable disease

- Good performance status (ECOG 0,1 or 2)

Exclusion Criteria:

- Previously treated with Oxaliplatin or Navelbine

- Symptomatic CNS metastases
Integrated Community Oncology Network
Jacksonville, Florida, United States
Status: Not yet recruiting
Contact: Diane Edwards, RN,OCN,CCRP - 904-363-7471 -
Integrated Community Oncology Network
Orange Park, Florida, United States
Status: Not yet recruiting
Contact: Carla Malott, RN - 904-272-3139 -
Integrated Community Oncology Network
Integrated Community Oncology Network
Record processing date processed this data on July 28, 2015 page